Indeed, administering EBRT prior to RLT led to higher tumor-absorbed doses by [177Lu]Lu-PSMA-617, as it was hypothesized based on the observed PSMA upregulation at 4 h post-irradiation in vitro. The gene discussed is FOLH1; the disease is neoplasm.